Navigation Links
'The Handbook of Proteins'
Date:1/22/2008

January 22, 2007, Weinheim, DE: Wiley-Blackwell, the scientific, technical, medical and scholarly publishing business of John Wiley & Sons, Inc., published a comprehensive resource for students and researchers studying protein structure and function.

Proteins are essential components of all living cells, playing key roles in both structure and function of each cell and, ultimately, the entire organism. Their activities include acting as signalling molecules, both messengers and receptors, and as enzymes executing most of the cells tasks.

Thorough knowledge of proteins, their structure, function and their interactions with other molecules in the body is important for the understanding of many diseases and also vital for developing appropriate therapies as many proteins are popular drug targets.

The Handbook of Proteins introduces the reader to the principles of protein biochemistry and at the same time describes traditional and state-of-the-art techniques for elucidating protein function and structure.

The 2 Volume Set consists of self-contained, peer-reviewed articles written by leading scientists in each field. The volumes feature introductory articles aimed at undergraduates and non-specialists, which provide basic information and a list of recommended further reading to encourage the reader to explore a topic in more depth. This approach helps the student reader progress from textbook material to primary literature. The introductory articles are complemented by advanced articles, written for postgraduate students and research workers. These contain more detailed information and key references allowing the reader to further investigate a specific area. This format allows professionals to use the books as a quick reference source.

Derived from the largest reference work in the Life Sciences, the acclaimed Encyclopedia of Life Sciences

  • Presented in full-colour throughout
  • Assembles more tha
    '/>"/>

Contact: Tina Heuberger
publicity@wiley-vch.de
49-062-016-06412
Wiley-Blackwell
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. NHCAA Releases Fraud Fighters Handbook Outlining Strategies to Protect the Public Against Health Care Fraud
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. Heat shock proteins are co-opted for cancer
4. Loss of gene leads to protein splicing and buildup of toxic proteins in neurons
5. Immune Proteins Warn of Early Lung Cancer
6. 2 proteins may be survival markers in some breast cancers
7. Scientists get first look at how water lubricates proteins
8. New Proteins That Help HIV Grow Identified
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Red Reflex Vision Exam Should Be Given to All Newborns Report Recommends 60862 1Red Reflex Vision Exam Should Be Given to All Newborns Report Recommends 60862 2Red Reflex Vision Exam Should Be Given to All Newborns Report Recommends 60862 3Journal of Public Health Management 26amp 3B Practice Calls for Growth in Public Health Workforce 60859 1Journal of Public Health Management 26amp 3B Practice Calls for Growth in Public Health Workforce 60859 2Journal of Public Health Management 26amp 3B Practice Calls for Growth in Public Health Workforce 60859 3Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 60856 1Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 60856 2Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 60856 3